Comprehensive analysis of the protein phosphatase 2A regulatory subunit B56ε in pan-cancer and its role and mechanism in hepatocellular carcinoma

Figure 1 Analysis of B56ε expression levels and prognostic value in 33 types of cancers. A: B56ε expression profile in pan-cancer by the Tumor Immune Estimation Resource database; B: B56ε expression in pan-carcinoma was analyzed based on The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression databases; C: Relationship between B56ε expression and tumor survival in the Gene Expression Omnibus dataset; D: Prognostic value of B56ε in pan-cancer based on TCGA database. ^aP < 0.05; ^bP < 0.01; ^cP < 0.001. OS: Overall survival; CI: Confidence interval; HR: Hazard ratio; ACC: Adrenocortical carcinoma; BLCA: Bladder urothelial carcinoma; BRCA: Breast invasive carcinoma; CESC: Cervical squamous cell carcinoma; CHOL: Cholangiocarcinoma; COAD: Colon adenocarcinoma; DLBC: Lymphoid neoplasm diffuse large B cell lymphoma; ESCA: Esophageal carcinoma; GBM: Glioblastoma; HNSC: Head and neck squamous cell carcinoma; KICH: Kidney chromophobe; KIRP: Kidney renal papillary cell carcinoma; KIRC: Kidney clear cell carcinoma; LGG: Low-grade glioma; LIHC: The Cancer Genome Atlas-Liver hepatocellular carcinoma; LUAD: Lung adenocarcinoma; LUSC: Lung squamous cell carcinoma; MESO: Mesothelioma; OV: Ovarian serous cystadenoma; PAAD: Pancreatic adenocarcinoma; PCPG: Pheochromocytoma and paraganglioma; PRAD: Prostate adenocarcinoma; READ: Rectal adenocarcinoma; SARC: Sarcoma; SKCM: Skin cutaneous melanoma; STAD: Stomach adenocarcinoma; TGCT: Testicular germ cell tumor; THCA: Thyroid carcinoma; THYM: Thymic carcinoma; UCEC: Endometrial cancer; UCS: Uterine carcinosarcoma; UVM: Uveal melanoma.